June 29, 2021
GSK Singapore has signed an Advance Purchase Agreement with the Government of Singapore for sotrovimab
Sotrovimab is currently undergoing review by the Singapore Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR) for interim authorization
Announcement follows the emergency use authorization (EUA) granted to sotrovimab by the US Food and Drug Administration (FDA) and a positive scientific opinion by the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP)
SINGAPORE, June 30, 2021 /PRNewswire/ GlaxoSmithKline Singapore and Vir Biotechnology announced an agreement with the Government of Singapore for the supply of sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of patients with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.